SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization ...
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback